Reply: The benefits and harms of breast cancer screening

The Lancet

Volumn 381, Issue 9869, 2013, Pages 799-800

  Donzelli, Alberto ^a  

^a Local Health Unit 32   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CLINICAL ASSESSMENT; DIAGNOSTIC ERROR; HUMAN; LETTER; MAMMOGRAPHY; PRIORITY JOURNAL; RANDOMIZATION; UNITED KINGDOM; BREAST TUMOR; EARLY DIAGNOSIS; FEMALE; MASS SCREENING; METHODOLOGY; NOTE;

BREAST NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING;

EID: 84874734393     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60619-4     Document Type: Letter

References (3)

1. Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 2012; 380: 1778-86.
2. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2009; 4: CD001877.
3. Euroscreen Working Group. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J Med Screen 2012; 19 (suppl 1): 5-13.